An anti-diabetogenic virus vaccine, which is currently under development66, might be a potent option to eliminate the potential viral contribution to β-cell destruction in patients taking immunosuppressant drugs such as TYK2 inhibitors and anti-CD3 antibodies, regardless of the mechanisms of T1D development induced by viruses. This evidence concerns the gene TYK2 and type 1 diabetes mellitus.